Targeted Pathway Inhibition in Patients With Pancreatic Cancer

This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic can

Trial Details

NCT ID

NCT04005690

Phase

EARLY_PHASE1

Sponsor

OHSU Knight Cancer Institute

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

Cobimetinib
Olaparib
Onvansertib
Azenosertib
Saruparib
Tremelimumab

Locations (sample)

Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

Ability to understand and the willingness to sign a written informed consent document
Age \>= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Clinically-confirmed diagnosis of resectable, borderline resectable, locally-advanced or metastatic adenocarcinoma of the pancreas.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →